| Literature DB >> 35106246 |
Shiho Amano1, Ryuichi Ohta2, Chiaki Sano3.
Abstract
Natural killer T cell intravascular lymphoma is a rare category of lymphoma among older individuals. The presentation of natural killer T cell lymphoma varies, causing diagnostic challenges for clinicians. Thus far, only a few studies have reported this condition in the context of musculoskeletal symptoms. We encountered a case of natural killer T cell intravascular lymphoma in a patient who presented with symptoms of sternoclavicular arthritis and femoral pain. The initial diagnosis was undifferentiated hematologic malignancy because undifferentiated hematologic malignant cells were seen on the bone marrow biopsy. Further examination showed that the patient had a high fever and abnormal cells in the blood. Flow cytometry findings revealed the abnormal cells as CD16 and CD56 positive, leading to the diagnosis of natural killer T cell intravascular lymphoma. This is the first report indicating the possibility of natural killer T cell intravascular lymphoma as one of the differential diagnoses of acute joint and muscular pains among older patients and the importance of assessing multiple organs, including musculoskeletal organs, to diagnose intravascular lymphoma.Entities:
Keywords: differential diagnoses; hematologic malignancy; intravascular lymphoma; natural killer t cell; older individuals; rural hospitals
Year: 2021 PMID: 35106246 PMCID: PMC8789203 DOI: 10.7759/cureus.20711
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Figure 1Ultrasound images of the left sternoclavicular joint
The image shows fine flow in the joint space (A: Plain, B: With fine flow)
Initial laboratory data of the patient
PT, prothrombin time; INR, international normalized ratio; APTT, activated partial thromboplastin time; UIBC, unsaturated iron-binding capacity; eGFR, estimated glomerular filtration rate; CK, creatine kinase; CRP, C-reactive protein; TSH, thyroid-stimulating hormone; T4, thyroxine; Ig, immunoglobulin; HBs, hepatitis B surface antigen; HBc, hepatitis B core antigen; HCV, hepatitis C virus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; EBV VCA, Epstein-Barr virus capsid antigen; EBNA, Epstein-Barr virus nuclear antigen; HIV, human immunodeficiency virus; and CMV, cytomegalovirus
| Maker | Level | Reference |
| White blood cells | 11.4 × 103 | 3.5–9.1 × 103/μL |
| Neutrophils | 72 | 44.0–72.0% |
| Lymphocytes | 6 | 18.0–59.0% |
| Monocytes | 21 | 0.0–12.0% |
| Eosinophils | 0 | 0.0–10.0% |
| Basophils | 0 | 0.0–3.0% |
| Red blood cells | 2.2 × 106 | 3.76–5.50 × 106/μL |
| Reticulocytes (%) | 5,304 (2.4) | /μL (%) |
| Hemoglobin | 6.8 | 11.3–15.2 g/dL |
| Hematocrit | 20.5 | 33.4–44.9% |
| Mean corpuscular volume | 92.7 | 79.0–100.0 fL |
| Platelets | 2.3 × 104 | 13.0–36.9 × 104/μL |
| PT-INR | 1.09 | |
| APTT | 29.7 | 25–40 seconds |
| Fibrinogen | 463.3 | 200–400 mg/dL |
| Fibrinogen degradation products | 13.1 | <5 μg/mL |
| Erythrocyte sedimentation rate | 110 | 2–10 mm/hour |
| Total protein | 7.7 | 6.5–8.3 g/dL |
| Albumin | 3.6 | 3.8–5.3 g/dL |
| Total bilirubin | 1.0 | 0.2–1.2 mg/dL |
| Direct bilirubin | 0.2 | 0–0.4 mg/dL |
| Aspartate aminotransferase | 19 | 8–38 IU/L |
| Alanine aminotransferase | 14 | 4–43 IU/L |
| Alkaline phosphatase | 239 | 106–322 U/L |
| γ-Glutamyl transpeptidase | 56 | <48 IU/L |
| Lactate dehydrogenase | 545 | 121–245 U/L |
| Uric acid | 4.5 | 3.0–6.9 mg/dL |
| Blood urea nitrogen | 10.7 | 8–20 mg/dL |
| Creatinine | 0.56 | 0.40–1.10 mg/dL |
| Serum Na | 139 | 135–150 mEq/L |
| Serum K | 3.4 | 3.5–5.3 mEq/L |
| Serum Cl | 104 | 98–110 mEq/L |
| Serum Ca | 9.7 | 3.5–10.2 mg/dL |
| Serum P | 2.9 | 0.2–1.2 mg/dL |
| Serum Mg | 2.1 | 1.8–2.3 mg/dL |
| Fe | 22 | 54–181 μg/dL |
| UIBC | 173 | 111–255 μg/dL |
| Ferritin | 1483.5 | 14.4–303.7 ng/mL |
| CK | 54 | 56–244 U/L |
| CRP | 16.91 | <0.30 mg/dL |
| Procalcitonin | 0.18 | 0–0.05 ng/mL |
| TSH | 1.61 | 0.35–4.94 μIU/mL |
| Free T4 | 1.4 | 0.70–1.48 ng/dL |
| Vitamin B12 | 459 | 180–914 pg/mL |
| Folic acid | 7.1 | >4.0 ng/mL |
| IgG | 1087 | 870–1700 mg/dL |
| IgM | 275 | 35–220 mg/dL |
| IgA | 166 | 110–410 mg/dL |
| IgE | 64 | <173 mg/dL |
| HBs antigen | 0.00 | IU/mL |
| HBs antibody | 0.79 | mIU/mL |
| HBc antibody | 0.08(-) | S/CO |
| HCV antibody | 0.05 | S/CO |
| Syphilis treponema antibody | 0.04 | S/CO |
| SARS-CoV-2 antigen | Negative | |
| EBV VCA IgG | 8.0(+) | |
| EBV VCA IgM | 0.4(-) | |
| EBV EBNA IgG | 1.3(+) | |
| HIV antigen antibody | Negative | |
| CMV antigenemia | Negative | |
| Free light chain κ/λ | 1.78 | |
| Urine test | ||
| Leukocyte | (-) | |
| Nitrite | (-) | |
| Protein | (+) | |
| Glucose | (-) | |
| Urobilinogen | (-) | |
| Bilirubin | (-) | |
| Ketone | (-) | |
| Blood | (+-) | |
| pH | 7.0 | |
| Specific gravity | 1.017 | |
| Fecal occult blood | (-) |
Figure 2Pathology of the bone marrow
Hematoxylin and eosin staining ×400 (HE) image showing leukocyte common antigen (LCA), Cytokeratin-multi-AE1/AE3 (AE1/AE3), Cytokeratin, CAM5 (CAM5), cluster of differentiation (CD), and myeloperoxidase (MPO)
Figure 3Contrast-enhanced computed tomography of the chest and computed tomography of the legs
Computed tomography findings of the leg showed occupied lesions in the bone marrow of the bilateral femur and pelvis (A) with white arrows
Contrast-enhanced computed tomography of the chest showing bilateral sternoclavicular joints (B) with white arrowheads
Figure 4Peripheral blood smear image
The image shows the appearance of blasts in the blood smear (May Grunwald Giemsa stain)
Figure 5Flow cytometry images
CD, cluster of differentiation; NC, negative control; TCR, T-cell receptor; MPO, myeloperoxidase; MPC-1, mitochondrial pyruvate carrier-1; SCC-H, side scatter height.